Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076461 | 0.98 | PKM (0.57) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL1718493 | 0.97 | PKM (0.51) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL19434452 | 0.93 | PKM (0.50) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL6342254 | 0.85 | PKM (0.44) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL1718320 | 0.85 | PIK3CD (0.45) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL1717485 | 0.85 | PKM (0.44) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL7883515 | 0.85 | PKM (0.48) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL6341184 | 0.85 | PKM (0.45) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL7880394 | 0.84 | ALOX15 (0.63) | PKMALOX15KDM4EKMT2AMEN1 | |
| SCHEMBL7880389 | 0.84 | CDK2 (0.48) | PKMKDM4EKMT2AMEN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621146-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-9969744-B2 | Compounds for use in cognition improvement | FUNDACIÓN LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-05-15 | — | — | US | disclosed |
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-03 | — | — | US | disclosed |
| EP-3177622-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | Fundacion para la Investigacion Medica Aplicada (ES) | 2017-06-14 | — | — | EP | disclosed |
| EP-2961741-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUND PARA LA INVESTIG MEDICA APLICADA (ES) | 2017-04-05 | — | — | EP | disclosed |
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| WO-2016020307-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-02-11 | — | — | WO | disclosed |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-01-07 | — | — | US | disclosed |
| EP-2961741-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2016-01-06 | — | — | EP | disclosed |
| US-9067945-B2 | Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes | Boehringer Ingehleim International GmbH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-1534713-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534711-A1 | PHENYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004026286-A2 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026286-A2 | SELECTIVE PHOSPHODIESTERASE 9A INHIBITORS AS MEDICAMENTS FOR IMPROVING COGNITIVE PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026876-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026876-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004018474-A1 | PHENYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018474-A1 | PHENYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | CHAT, NLN, GRIN2C | PKM 1516/4885ALOX15 922/4885KDM4E 2381/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | PKM 155/4885ALOX15 3258/4885KDM4E 1745/4885 |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | PDE1A, HDAC1, HDAC2 | PKM 840/4885ALOX15 1610/4885KDM4E 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.